BackKalVista Pharmaceuticals Overview

KalVista Pharmaceuticals Receivables

Latest receivables for KALV: $11M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$11.30M

Peer trimmed avg / median

Loading

KalVista Pharmaceuticals Receivables History

Loading

KalVista Pharmaceuticals vs. peers: Receivables Comparison

Loading

KalVista Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

KalVista Pharmaceuticals (KALV) FAQ

KalVista Pharmaceuticals (KALV) currently reports a receivables of $11M as of January 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore KalVista Pharmaceuticals's receivables history and peer comparisons.

KalVista Pharmaceuticals's receivables changed from $0 to $11M (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

KalVista Pharmaceuticals reported $11M in receivables as of January 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for KalVista Pharmaceuticals, and consider following KALV for alerts when major investors trade the stock.

KalVista Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KALV with unrelated industries.